Cogent Biosciences, Inc.
Financials
Valuation Metrics
Cogent Biosciences, Inc.'s Market Cap is $5.67B. At end of 2025 it was $2.40B. Ranked #1265 of 3,121 in US market (top 41%), #426 of 1,463 on NASDAQ (top 29%), #74 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 28%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $5.67B | US#1,265/3,121 Sec#74/266 |
| Revenue | $0.00 | US#2,889/3,121 Sec#196/266 |
| Net Income | $-377M | US—/3,121 Sec—/266 |
| Total Assets | $835M | US#2,553/3,121 Sec#116/266 |
| Net Assets | $532M | US#2,195/3,121 Sec#103/266 |
| Employees | 258 | US#2,452/3,121 Sec#121/266 |
| Value | ||
| P/B | 10.65x | US#2,638/3,121 Sec#199/266 |
| FCF Yield | -5.45% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -70.85% | US#2,754/3,121 Sec#187/266 |
| ROA | -45.20% | US#2,969/3,121 Sec#200/266 |
| Financial Health | ||
| Debt Ratio | 56.76% | US#651/3,121 Sec#143/266 |
| Total Debt | $244M | US#2,187/3,121 Sec#91/266 |
| FCF | $-309M | US#2,853/3,121 Sec#235/266 |
| Cash | $181M | US#1,815/3,121 Sec#120/266 |
| Current Ratio | 13.57x | US#187/3,121 Sec#57/266 |
| Performance | ||
| 1Y Return | 168.53% | US#87/3,121 Sec#34/266 |
| 1M Return | -11.26% | US#2,555/3,121 Sec#197/266 |
| From 52W High | -24.10% | US#1,745/3,121 Sec#133/266 |
| 1Y MDD | -26.34% | US#1,148/3,121 Sec#63/266 |
| Trading | ||
| Volume | 1,129,029 shares | US#1,296/3,121 Sec#138/266 |
| Trading Value | $38M | US#1,466/3,121 Sec#114/266 |
| Per Share | ||
| EPS | $-2.21 | US—/3,121 Sec—/266 |
| BPS | $3.12 | US#2,480/3,121 Sec#162/266 |
Company Info
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.